Agilent Technologies has an average rating of overweight and mean price target of $181.89, according to analysts polled by FactSet.
NH Investment & Securities values Lunit's SCOPE AI pathology and biomarker business at more than 500 billion won, with 2027 ...
Financial News] NH Investment & Securities said Lunit could be revalued in terms of its business as a company in the AI drug-development value chain, rather than simply as an AI imaging diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results